1Blum JL,Dieras V,Lo Russo PM,et al.Multicenter,phase Ⅱ study of capecitabine in taxane-pretreated metastatic breast carcinoma patients[J].Cancer,2001,92(7):1759 -1768.
2Miller AB,Hoogstraten B,Staquet M,et al.Reporting results of cancer treatment[J].Cancer,1981,47(1):207-214.
3Johnson SA,Harper P,Hortobagyi GN,et al.Vinorelbine on overview[J].Cancer Treat Rew,1996,22(2):127-142.
6Blum JL,Jones SE,Buzdar AU,et al.Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[J].J Clin Oncol,1999,17 (2):485-493.
8Ishitsuka H.Capecitabine:preclinical pharmacology studies[J].Invest New Drugs,2000,18(4):343-354.
9Nole F,Catania C,Mandala M,et al.Phase Ⅰ study of vinrelbine (V)and capecitabine(C)in advanced breast cancer (ABC)[J].Breast Cancer Res Treat,2000,64:125.
2Miller AB,Hoogslralen B, Staquel M, et al. Reporting resuits of cancer treatment [J]. Cancer, 1981,47(1) :207.
3Martin M. Platinum compounds in the treatment of advanced breasl cancer[J]. Clin Breast Cancer, 2001,2 (3) :190.
4Vassilomanolakis M, Koumakis G, Barbounis V, et al. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines [J]. Ann Oncol,.2000,11(9):1155.
5Ray-Coquard I,Biron P,Bachelot T, et al. Vinorebine and cisplatin for the treatment of metastatic breast carcinoma after failure of anthracycline-and(or) paclitaxel-contaning regimens[J]. Cancer, 1998,82(1) : 134.
6GunelN,Akcali Z,Yamac D,et al. Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer[J].Tumori,2000,86(4):283.
7Gebbia V, Testa A, Borsellino N, et al. Cisplatin and vinorebine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen[J]. Ann Oncol,2001,12(6) :767.
8Gieschke R, Reigner B, Blesch KS, et al. Population pharmacokinetic analysis of the major metabolites of capecitabine [J]. J Pharmacokinet pharmacodyn, 2002;29(1):25～47.
9Nole F, Catania C, Mandala M, et al. Fhase Ⅰ study of vinrelbine (V) and capecitabine (C) in advanced breast cancer (A B C) [J]. Brest Cancer Res Treat, 2000;64:125.
10Blum JL, Jones SB, Buzdar ALL, et al. Multicenter phasc Ⅱ study of capecitabine in paclitaxel refractory metastatic breast cancer. J Clin Oncol, 1999;17:485～493.
4Romero Acuna L, Langhi M, PerezJ, et al. Vinorelbine and paclitaxel as ftrst-line chemotherapy in metastatic breast cancer[J]. J Clin Oncol, 1999, 17(1): 74-81.
5孙燕,周际昌,主编.临床肿瘤内科手册[M].上海:上海科学技术出版社,2003.106-107.
6Shamseddine A, Khalifeh M, Chehal A, et al. A clinical phase Ⅱ study of cisplatinum and vinorelbine(PVn) in advanced breast carcinoma (ABC)[J]. AmJ Clin Oncol, 2005, 28(4): 393-398.
7Vassilomanolakis M, Koumakis G, Demiri M, et al. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment [J]. Cancer Invest, 2003, 21(4):497-504.
8Gieschke R, Reigner B, Blesch KS et al. Population pharmacokinetic analysis of the major metabolites of capecitabine[J]. J Pharmacokinet Pharmacodyn, 2002, 29 (1): 25-47.
9Talbot DC, Mbiseyenko V, Van Belie S, et al. Randomised, phase Ⅱ trial comparing oral capecitabine(Xeloeda) with paclitaxei in patients with metastatic/advanced breast cancer pretreated with anthracyclines[J]. BrJ Cancer, 2002, 86(2): 1367-1372.
10Seidman AD, O'shaughnessy J, Misset JL. Single-agent capecitabine:a reference treatment for taxane-pretreated metastatic breast cancer[J]. Oncologist, 2002, 7(Suppl 6): 20-28.
